202
Articles
16.7K
Citations
9
avg. Impact Factor
69
h-index

Most Cited Articles of Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery in 2017

TitleJournalYearCitations
Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized ApproachesImmunity2017204
The HIV-1 envelope glycoprotein structure: nailing down a moving targetImmunological Reviews2017178
Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaquesScience2017176
Open and closed structures reveal allostery and pliability in the HIV-1 envelope spikeNature2017155
A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic β-Hairpin StructureImmunity2017146
Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controllerScience Translational Medicine201796
HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody LineageImmunity201771
Neutralizing human monoclonal antibodies prevent Zika virus infection in macaquesScience Translational Medicine201769
Developing an HIV vaccineScience201768
Lipid interactions and angle of approach to the HIV-1 viral membrane of broadly neutralizing antibody 10E8: Insights for vaccine and therapeutic designPLoS Pathogens201742
Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal ModelCell Reports201740
Glycans Function as Anchors for Antibodies and Help Drive HIV Broadly Neutralizing Antibody DevelopmentImmunity201729
Targeted N-glycan deletion at the receptor-binding site retains HIV Env NFL trimer integrity and accelerates the elicited antibody responsePLoS Pathogens201728
First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost RegimensJournal of Infectious Diseases201725
Cryopreservation-related loss of antigen-specific IFNγ producing CD4 T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine trial substudyVaccine201724
Evaluating the Impact of Functional Genetic Variation on HIV-1 ControlJournal of Infectious Diseases201718
Combined skin and muscle vaccination differentially impact the quality of effector T cell functions: the CUTHIVAC-001 randomized trialScientific Reports201717
High-Throughput Protein Engineering Improves the Antigenicity and Stability of Soluble HIV-1 Envelope Glycoprotein SOSIP TrimersJournal of Virology201717
A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine RegimensFrontiers in Immunology201713
Stabilization of a soluble, native-like trimeric form of an efficiently cleaved Indian HIV-1 clade C envelope glycoproteinJournal of Biological Chemistry201711
Characterization of a stable HIV-1 B/C recombinant, soluble, and trimeric envelope glycoprotein (Env) highly resistant to CD4-induced conformational changesJournal of Biological Chemistry201711
Glutaraldehyde Cross-linking of HIV-1 Env Trimers Skews the Antibody Subclass Response in MiceFrontiers in Immunology20175
No Evidence for Association of β-Defensin Genomic Copy Number with HIV Susceptibility, HIV Load during Clinical Latency, or Progression to AIDSAnnals of Human Genetics20174